

Principles for Home Delivery of Clotting Factor

Preamble

Home delivery of clotting factor is being made increasingly available to haemophilia patients in Australia. A number of haemophilia centres have developed and trialed home delivery programs with high levels of satisfaction from patients and staff as well as successful stock management. Clinical oversight is vital to ensure each patient's treatment regime is closely monitored and clotting factor is used appropriately.

Definitions

HTC: Haemophilia Treatment Centre (refer to Appendix for list of designated HTCs in Australia)

Home delivery is the delivery of haemophilia treatment products by Baxter Healthcare or Wyeth/Pfizer directly to the patient's home or workplace usually on a monthly basis.

CNC: Clinical Nurse Consultant/Coordinator

Aim

The purpose of this document is to provide guiding principles for establishing home delivery of clotting factor in order to ensure:

- Patients are maintained on an appropriate dosing regime with expert clinical oversight
- Clotting factor is managed responsibly with minimal wastage
- HTC staff, patients/nominated representatives and pharmaceutical companies are aware of their responsibilities in the home delivery process

Initiating home delivery

Home delivery should be initiated by the patient's designated HTC and prescribed by the HTC Director/Consultant Haematologist or by a staff member under their direct supervision.

The patient must sign a privacy agreement (and any other required paperwork) with the supplier prior to commencement of home delivery.

Patient Requirements

Patients must be able to meet the requirements for the home delivery program as described by the designated HTC.

Typical requirements include:

- Being available to contact for regular stock checks and to confirm delivery dates
- Being available to accept clotting factor deliveries
- Notifying the HTC of any changes to clotting factor requirements/deliveries e.g. bleeding episodes, holidays
- Attending the HTC for regular clinic appointments

Monitoring of Stock

A maximum stock level of clotting factor to be held by the patient is set according to their dosing regime and frequency of delivery and allowing a buffer of extra doses should a bleeding episode occur.

Prior to each delivery the patient or nominated representative is contacted by the HTC or supplier for a stock check in order to determine the amount of clotting factor to be supplied at the next delivery and to prevent oversupply.

Ongoing approval of orders

Once a dosing regimen is established every order must be approved by the Haemophilia CNC or an appointed representative (covering nurse, registrar, product manager) at the designated HTC.

Change of dosing regimen

Any change to dosing regimen such as increased frequency or increased dosage must be approved by the designated HTC Director/Consultant Haematologist or by a staff member under their direct supervision.

Deliveries

The patient/nominated representative must be on hand to receive their product delivery. Deliveries should never be left at an unattended address.

The HTC should instruct the pharmaceutical company of actions to take should no one be at home to receive the delivery, for example:

- Contact HTC staff
- Product returned to the company warehouse
- Product delivered to the HTC/local hospital

Patient Education/Responsibilities

In addition to the education and training provided for patients/nominated representatives undertaking home treatment, education should be provided regarding:

- Requirements for home delivery as determined by the designated HTC
- Checking each delivery is the correct product and dose
- Storage of clotting factor and stock rotation

Pharmaceutical Companies

HTCs should have processes in place with the pharmaceutical companies to address:

- The role of the pharmaceutical company in performing stock checks if applicable
- Steps to take should a patient/nominated representative not be at home to accept a delivery
- Approval of ongoing orders
- Approval of changes to product dosage/quantities.

Should a patient/nominated representative be unable to meet the requirements for home delivery such as regular contact for stock checks and being available to receive deliveries the HTC should reconsider the suitability of home delivery for that individual.

This document is intended to assist HTCs by providing guiding principles. Every HTC will need to tailor its home delivery program to suit their patient population, level of staffing and the hospital systems they must adhere to.

APPENDIX

Location of Designated Haemophilia Treatment Centres in Australia:

The Alfred Hospital, VIC
The Royal Children's Hospital, VIC
Royal Darwin Hospital, NT
Royal Hobart Hospital, TAS
Princess Margaret Hospital, WA
Royal Brisbane & Women's Hospital, QLD
Children's Hospital at Westmead, NSW
Fremantle Hospital, WA
The Canberra Hospital, ACT
Newcastle Mater Misericordiae Hospital, NSW
Women's and Children's Hospital, SA
Royal Perth Hospital, WA
Royal Prince Alfred Hospital, NSW
Royal Adelaide Hospital, SA
Royal Children's Hospital, QLD
Sydney Children's Hospital, NSW
Westmead Hospital, NSW
The Prince of Wales Hospital, NSW